PRA

ProAssurance has effectively ceased to be a standalone equity. Per the 10-K MD&A, it signed a merger agreement with The Doctors Company on March 19, 2025; shareholders approved it on June 24, 2025, the FTC granted HSR early termination on July 2, 2025, and final insurance-regulator approvals are already in hand in six states plus Lloyd's and the Cayman Islands — with only California and Pennsylvania still pending. At $25.00 the stock trades on deal completion probability, not on earnings power. Because the provided data does not disclose the per-share merger consideration, I will not guess a price target; the practical question for a holder is simply whether the remaining two regulatory approvals come through, and the breadth of approvals already secured suggests that base rate is favorable.

The standalone fundamentals reinforce why management sold rather than fought the cycle. FY2025 revenue fell 4.6% to $1.10B and net income slipped to $50.9M, leaving a 4.6% net margin and a 3.8% ROE — barely a third of the company's own stated dynamic ROE target of roughly 11.2% (700bps over the 10-year Treasury). The five-year earnings record is volatile and structurally weak: net income swung from $144M (FY2021) to a -$402K loss (FY2022) to -$38.6M (FY2023) before recovering to ~$51-53M. Most telling, operating cash flow turned negative at -$25.6M (down 139%), cash fell 33.5% to $36.5M, the dividend is zero, and liabilities run 3.04x equity — a profile consistent with a sub-scale medical professional liability writer struggling against the soft-market price competition and tort/severity pressures the Risk Factors describe at length.